drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific antibody)
drug_description
Intact bispecific IgG antibody with specificity for CD19 and CD20; covalently linked to NK cell surfaces to enable dual-antigen recognition, stable immune synapse formation, and ADCC against B‑cell lymphomas.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
OTHER ENGINEERED IMMUNE CELL
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Non–genetically modified NK cells are covalently coated with an intact CD19/CD20 bispecific IgG, enabling dual-antigen recognition on B‑cell lymphomas, stabilizing the immune synapse, and enhancing NK effector functions. The armed NK cells kill target cells via degranulation (perforin/granzyme) and Fc-mediated ADCC against CD19+/CD20+ B-cell tumors.
drug_name
CD19/CD20 bispecific antibody (tethered to NK cells)
nct_id_drug_ref
NCT06693973